A groundbreaking phase 3 clinical trial reveals that a personalized mRNA vaccine from Merck and Moderna significantly cuts the risk of melanoma returning.
Inc.com
This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent
Shown as published in the source's RSS feed. IndiaAIFounders doesn't link out to third-party sites — this is the complete detail available from the feed itself.